Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

May 31, 2025

Conditions
Asthma ExacerbationEmergency DepartmentNebulization
Interventions
DEVICE

continuous nebulization

continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min

DEVICE

Intermittent nebulization

intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour

All Listed Sponsors
lead

Thammasat University

OTHER

NCT06291740 - Continuous Versus Intermittent Nebulization Therapy in Acute Asthma Exacerbation at Emergency Department | Biotech Hunter | Biotech Hunter